Skip to Content

Doxylamine / pyridoxine Pregnancy and Breastfeeding Warnings

Doxylamine / pyridoxine is also known as: Bonjesta, Diclegis

Doxylamine / pyridoxine Pregnancy Warnings

FDA pregnancy category: A Use of doxylamine succinate and pyridoxine hydrochloride is considered acceptable.

Treatment of animals during organogenesis with doses 60 to 100 times the highest clinical dose resulted in increased fetal resorptions, decreased fetal body weight and increased skeletal variations with reduce ossifications. Another study of animals treated during organogenesis with doses up to 3.2 times the highest clinical dose showed no malformations or evidence of embryo, fetal or maternal toxicity. A similar animal study observed ventricular septal defects (VSDs) in preterm fetuses at doses 0.5 to 20 times higher than the clinical dose, but there were no VSDs seen in animals at term. Epidemiological studies reported no increased risk for malformation from first trimester exposures as well as no statistical significant relationships between fetal abnormalities and first trimester use. FDA pregnancy category A: Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).

See references

Doxylamine / pyridoxine Breastfeeding Warnings

Excitement, irritability and sedation have been reported in nursing infants presumably exposed to doxylamine succinate. There have been no reports of adverse effects in nursing infants presumably exposed to pyridoxine hydrochloride.

Doxylamine succinate and Pyridoxine should not be used in nursing women. Doxylamine Succinate: Excreted into human milk: Unknown (Doxylamine Succinate); Yes (Pyridoxine) Excreted into animal milk: Unknown (Doxylamine Succinate and Pyridoxine) The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Diclegis (doxylamine-pyridoxine)." Duchesnay USA Inc, Rosemont, PA.

References for breastfeeding information

  1. "Product Information. Diclegis (doxylamine-pyridoxine)." Duchesnay USA Inc, Rosemont, PA.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.